Eli Lilly And Co (NYSE:LLY) stock is up 7.7% to trade at $1,080.69 at last glance, after the pharmaceutical name reported a top- and bottom-line beat for the fourth quarter and issued an upbeat forecast for 2026. The company attributed the strong showing to Zepbound and Mounjaro sales. LLY is today pacing for for its best day since October as it tests overhead pressure at the $1,100 level, which has kept price action in check since a Jan. 8, record high of $1,113.98. The equity is bouncing off the rising 80 ...

Group 1: Market Overview - US stock futures are mixed following a tech-led sell-off, particularly affecting software stocks due to fears of AI disruption [1][5] - Nvidia's CEO Jensen Wong dismissed concerns about AI replacing software, calling such ideas illogical [1][6] - Investors are rotating out of risk assets, with Bitcoin briefly falling below $73,000, marking a 14% decline since the start of the year and a 40% drop from its record high in October [3][4] Group 2: Earnings Highlights - AMD reported fourth-quarter earnings that exceeded estimates, but its first-quarter forecast disappointed investors, leading to a decline in its stock [2][15] - Eli Lilly projected a significant sales increase of up to 27% this year, reaching $83 billion, driven by its diabetes and obesity drugs [8][9] - Uber announced a new CFO amid disappointing earnings forecasts, with adjusted earnings per share expected to be lower than analysts' expectations [10][11] Group 3: Company-Specific Insights - Chipotle's earnings report indicated flat comparable sales for the year, with plans to open 370 new stores to improve performance after a 39% stock decline last year [12][13] - Analysts noted that AMD's strong revenue included $390 million from China, but there are concerns about the sustainability of this revenue [17][19] - The upcoming launch of AMD's Helios system is anticipated to close the performance gap with Nvidia, with significant volumes expected in the fourth quarter [22][25] Group 4: Broader Industry Trends - The AI trade is experiencing reassessment, with concerns about the impact of AI on software businesses leading to significant stock declines [48][49] - Analysts suggest that the selling in the software sector may be overdone, indicating potential for recovery as companies adapt to AI technologies [49][50] - The semiconductor industry is under pressure, with high expectations for companies like Nvidia and Broadcom to meet market demands [27][28]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Market Overview - Major U.S. stock market indices experienced a decline on February 3 due to a tech sell-off, particularly affecting software stocks as fears arose that AI could replace traditional software models [1] - Geopolitical tensions, particularly between the U.S. and Iran, have added to market unease, emphasizing the importance of fundamentals in the current high-rate environment [2] Value Investing Focus - The current market conditions are driving a renewed focus on value investing, which seeks fundamentally strong stocks trading below their intrinsic value [11] - Earnings yield is a key metric for value investors, calculated as earnings per share (EPS) divided by the current stock price, indicating potential undervaluation [5] Stock Picks - Harmony Biosciences Holdings Inc. (HRMY) is noted for its focus on therapies for rare neurological disorders, with a projected 2026 sales growth of 17% and earnings growth of 27% [12] - Adecoagro S.A. (AGRO) is highlighted for its agricultural operations, with a projected 2026 sales growth of 30% and an impressive earnings growth of 452% [13] - Sociedad Quimica y Minera de Chile S.A. (SQM) is recognized for its production of specialty nutrients and lithium derivatives, with projected sales growth of 55% and earnings growth of 181% by 2026 [14] - Angi, Inc. (ANGI) operates a digital marketplace for home services, with expected sales growth of 3% and earnings growth of 36% by 2026 [15] - PHINIA Inc. (PHIN) specializes in automotive systems, with projected sales growth of 2% and earnings growth of 15% by 2026 [16]

Core Insights - Novartis AG reported fourth-quarter core earnings per share of $2.03, exceeding the Zacks Consensus Estimate of $1.99 and up from $1.98 a year ago [1][7] - Core net income decreased by 1% to $3.9 billion, while revenues of $13.3 billion fell short of the Zacks Consensus Estimate of $13.7 billion, despite a 1% year-over-year increase [2][7] - The company faced revenue pressure from generic competition for key drugs Entresto and Promacta, leading to a 1% decline in sales on a constant currency basis [2][26] Financial Performance - Core operating income improved by 1% to $4.9 billion, supported by higher government grant income and lower SG&A expenses, although offset by increased R&D expenses [19] - For 2025, Novartis reported sales growth of 8% to $54.53 billion, surpassing the Zacks Consensus Estimate, with core EPS increasing by 17% to $8.98 [20] - Guidance for 2026 indicates low single-digit growth in net sales on a constant currency basis, with core operating income expected to decline in low single digits [21] Drug Performance - Cosentyx sales rose 11% to $1.8 billion, driven by strong demand across all regions [5] - Kisqali sales surged 44% to $1.32 billion, although it missed estimates, with underlying global growth at 54% [6][8] - Entresto sales plummeted 45% to $1.2 billion due to generic competition, while Promacta sales fell 63% to $226 million [8][13] - Pluvicto sales increased by 70% to $605 million, driven by strong demand following recent approvals [11] - Kesimpta sales grew 27% to $1.2 billion, while Jakavi sales increased by 8% to $555 million [10][12] Strategic Updates - Novartis announced plans to acquire Avidity Biosciences for $12 billion to enhance its late-stage neuroscience pipeline [22][23] - The acquisition aims to strengthen the company's position in addressing genetic neuromuscular diseases [28] - A collaboration agreement with the U.S. government was established to reduce drug prices while supporting ongoing investments in manufacturing and R&D [25] Market Position - Novartis shares have gained 42.1% over the past year, outperforming the industry growth of 19% [2] - The company is navigating significant patent expirations, with a focus on key growth drivers such as Kisqali, Kesimpta, Pluvicto, and Scemblix [26][27]

Key Takeaways NVO shares slumped 15% after a conservative outlook pointed to a 5-13% sales decline in 2026. Novo Nordisk cited U.S. pricing pressure and semaglutide patent expiries as key drags. NVO highlighted new U.S. leadership and wider Wegovy rollout, boosting appeal of diversified ETFs. Shares of Danish drugmaker Novo Nordisk (NVO) suffered a sharp slump of 15% on the bourses on Tuesday, after the company issued a conservative sales outlook that implied a 5-13% decline in 2026 from last year. This new ...

Core Insights - GSK's fourth-quarter results exceeded expectations, with revenue of £8.6 billion reflecting an 8% increase at constant exchange rates and core EPS rising by 14%, indicating strong performance [3][4] - The company has achieved its medium-term targets a year ahead of schedule, with sales growth and earnings progression aligning with management's projections for 2026 [4] - GSK's long-term revenue ambition of over £40 billion by 2031 was reiterated, showcasing confidence in future growth [4] Financial Performance - Specialty Medicines were a significant growth driver, increasing by 18% in the quarter, primarily due to injectable HIV products and oncology [5] - Vaccines, particularly Shingrix and the RSV vaccine Arexvy, also exceeded forecasts, compensating for a slight decline in General Medicines [5] - Cost control measures, including lower legal expenses and a favorable tax outcome, positively impacted earnings, while increased R&D spending indicates a focus on future investments [6] Guidance Outlook - For 2026, GSK has set a cautious sales growth guidance of 4-6% at constant exchange rates, incorporating a significant foreign exchange headwind [7] - Analysts view this guidance as a low bar, with consensus expectations already near the upper limit of the range, suggesting that GSK's performance could surpass these projections [8]

All right, joining me right now to talk about some of the stocks to watch and moves. Diane King Hall is with me and first up Diane, we're looking at Nphase and it was running right. >> Oh my goodness, eyepopping move here.I wasn't even expecting it to uh be this high out the gate. Up more than 31% off the back of its quarterly results. Uh let's go through the numbers for InPhase.Uh adjusted earnings per share came in at 71 cents. Uh Street was looking for 54 cents. So that's a big beat there.revenue coming ...

Group 1 - AbbVie reported adjusted earnings of $2.71 per share on $16.62 billion in fourth-quarter sales, surpassing analyst expectations of $2.65 per share and $16.41 billion in sales [1] - The company's earnings per share increased from $2.16 in the same period last year, while sales rose from $15.1 billion [1] - AbbVie's immunology products, Rinvoq and Skyrizi, continue to drive growth, contributing to a strong performance despite the stock slump [1] Group 2 - The stock of AbbVie experienced a decline early Wednesday despite the positive earnings report and guidance [1] - Analysts had anticipated a better market reaction given the earnings beat, indicating potential market volatility or investor sentiment issues [1] - The overall market context included a surge in the Russell 2000 index, highlighting a mixed performance among small-cap stocks [1]

Core Insights - Novo Nordisk A/S reported adjusted fourth-quarter 2025 earnings of $1 per ADR, exceeding the Zacks Consensus Estimate of 90 cents, but down from $0.98 per ADR in the same quarter last year [2][4] - Revenues for the quarter were $12.34 billion, an 8% decline year over year in DKK and a 2% decline at constant exchange rates, primarily due to lower-than-expected sales in Diabetes and Obesity Care [3][4] - Despite beating earnings estimates, Novo Nordisk's shares fell 14.6% as investors reacted negatively to the company's poor sales and operating profit outlook for 2026 [4][9] Financial Performance - The Diabetes and Obesity Care segment reported sales of DKK 73.8 billion, a 2% decline, with notable changes in product sales: Fiasp up 154%, NovoRapid down 24%, and Human insulin down 24% [6] - Ozempic sales were DKK 31.83 billion, up 1%, while Rybelsus sales fell 19% to DKK 5.30 billion [7] - Obesity Care sales increased 11% to DKK 22.45 billion, with Wegovy's sales growth slowing to 17% due to competition and illegal market versions [8] 2026 Outlook - Novo Nordisk expects adjusted sales and operating profit to decline by 5-13% at constant exchange rates in 2026, with further declines expected when translated into DKK due to adverse FX movements [9][17] - The guidance indicates a potential negative sales growth of -1% and modest operating profit growth of 11%, highlighting reliance on non-recurring accounting benefits [17][21] - The company faces challenges from slowing prescription trends, increased competition, and pricing pressures, particularly in the U.S. market [18][21] Competitive Landscape - Eli Lilly is gaining market share in diabetes and obesity, raising concerns about Novo Nordisk's ability to maintain its competitive edge [22] - The launch of oral Wegovy is seen as a potential differentiator, but historical trends suggest that late entrants can still dominate the market [22] Investment Sentiment - The market reaction reflects investor disappointment with the slowing core momentum in diabetes and obesity franchises, ongoing pricing pressures, and rising investment intensity [20][21] - Novo Nordisk's stock is currently rated Zacks Rank 4 (Sell), indicating a cautious outlook among analysts [23]